Form 4: ImmuCell Corp Director Rosgen Acquires 10,000 Stock Options

Director Steven T. Rosgen acquired 10,000 non-qualified stock options in ImmuCell Corporation on September 20, 2024.

Summary

• On September 20, 2024, Steven T. Rosgen, a director of ImmuCell Corporation, acquired 10,000 non-qualified stock options.
• The exercise price of these options is $3.60.
• The options are exercisable starting September 20, 2027, and expire on September 20, 2029.
• Following the transaction, Rosgen beneficially owns 10,000 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates